Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- AusperBio Therapeutics Inc.
- Study ID
- NCT07654283
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Hepatitis B, Chronic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- AHB-137 — DRUGSubcutaneous injection
Study Details
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
Key Dates
- Start date
- Jun 17, 2026
- Status verified
- Jun 2026
- Primary completion
- Mar 24, 2027
- Completion
- Jul 26, 2028
Study Design
- Enrollment
- 70 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Dose Regimen AParticipants receive AHB-137 according to dosing regimen A.
- Experimental: Arm B: Dose Regimen BParticipants receive AHB-137 according to dosing regimen B.
Primary Outcome Measure
Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) [ Time Frame: 24 Weeks post AHB-137 treatment (Week 48) ]
Central Contacts
- Maggie Davis(650) 650-2877
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304-1509 | - |
| University of Maryland | Baltimore | Maryland | 21201-1009 | - |
| NYU Langone Health | New York | New York | 10016 | - |
| Texas Liver Institute | San Antonio | Texas | 78215-2100 | - |